Zogenix Inc (ZGNX)

10.85
NASDAQ : Health Care
Prev Close 10.85
Day Low/High 0.00 / 0.00
52 Wk Low/High 7.33 / 13.70
Avg Volume 287.30K
Exchange NASDAQ
Shares Outstanding 24.79M
Market Cap 260.31M
EPS 1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These 5 Stocks Under $10 Could Light Up Soon

These 5 Stocks Under $10 Could Light Up Soon

Here's a technical look at how to trade several under $10 stocks that could trigger big breakout trades soon.

Zogenix Announces Issuance Of U.S. Patent For ZX008 In Dravet Syndrome

Zogenix Announces Issuance Of U.S. Patent For ZX008 In Dravet Syndrome

Issued Patent is First Covering Company's Treatment of Seizures Associated with Dravet Syndrome Using Fenfluramine as an Adjunctive Therapy

Zogenix Announces CFO Transition

Zogenix Announces CFO Transition

Ann D. Rhoads to Depart Company Following Transition Period; Biopharmaceutical Industry Veteran Michael P. Smith Appointed New CFO

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Depomed Reports Dip in Earnings, Reduces Revenue Guidance

Depomed Reports Dip in Earnings, Reduces Revenue Guidance

Despite a win in court over its patents and a deal with activist investors, Depomed shares dropped after it gave a reduced guidance for 2016 revenues.

Zogenix Provides Corporate Update And Reports Third Quarter 2016 Financial Results

Zogenix Provides Corporate Update And Reports Third Quarter 2016 Financial Results

Company will host a conference call today at 4:30 p.m. EST/1:30 p.m. PST

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

Shares of Omeros fell almost 10% after analysts' downgraded the biotech.

Zogenix To Have Significant Presence At 12th European Congress On Epileptology

Zogenix To Have Significant Presence At 12th European Congress On Epileptology

Company's Four Poster Presentations to Focus on ZX008 Open-Label Cohort and Burden of Dravet Syndrome

Zogenix Provides Corporate Update And Reports Second Quarter 2016 Financial Results

Zogenix Provides Corporate Update And Reports Second Quarter 2016 Financial Results

Company will host a conference call today at 4:30 p.m. EDT/1:30 p.m. PDT

Commit To Buy Zogenix At $5, Earn 9.6% Annualized Using Options

Commit To Buy Zogenix At $5, Earn 9.6% Annualized Using Options

Investors eyeing a purchase of Zogenix Inc. stock, but cautious about paying the going market price of $8.98/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Zogenix Becomes Oversold (ZGNX)

Zogenix Becomes Oversold (ZGNX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Zogenix Provides Corporate Update And Reports First Quarter 2016 Financial Results

Zogenix Provides Corporate Update And Reports First Quarter 2016 Financial Results

Company will host a conference call today at 4:30 p.m. EDT/1:30 p.m. PDT

New Data On Zogenix's ZX008 For Dravet Syndrome To Be Presented At 14th International Child Neurology Congress

New Data On Zogenix's ZX008 For Dravet Syndrome To Be Presented At 14th International Child Neurology Congress

Podium Presentation to Highlight Efficacy, Cardiovascular Safety, Sleep Quality, and Quality of Life in Patients Receiving Low-Dose Fenfluramine for the Treatment of Dravet Syndrome

ZGNX: Insiders vs. Shorts

ZGNX: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 03/01/2016 settlement date, and Zogenix Inc. is one of the most shorted stocks of the Russell 3000, based on 18.11 "days to cover" versus the median component at 5.60.